|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
RGD |
Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats.
|
21905004 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, mast cells expressed significantly more interleukin-17 (IL-17) in SpA than in RA synovitis, and mast cells constituted the major IL-17-expressing cell population in the SpA synovium.
|
21968742 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis.
|
22269151 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cell surface HLA-B27 FHC binding to these immune receptors or acting through other mechanisms could impact on the pathogenesis of spondyloarthritis by promoting immune cell production of IL-17.
|
23910730 |
2014 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA.
|
28149838 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.
|
28270233 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis.
|
28390966 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, IL-17 and IL-23 inhibitors reduce the clinical manifestations of SpA.
|
28850053 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes.
|
29142230 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A has been identified as a master cytokine in the inflammatory response and pathogenesis of PsA and spondyloarthritis in general.
|
29187009 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Targeted Delivery of the HLA-B<sup>∗</sup>27-Binding Peptide into the Endoplasmic Reticulum Suppresses the IL-23/IL-17 Axis of Immune Cells in Spondylarthritis.
|
29463951 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Other targeted cytokines associated with IL-17 axis in SpA will also be included.
|
29670461 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α.
|
29751976 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA.
|
29869838 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the contribution of IL-17-producing γδ T cells to SpA pathogenesis is certainly not an open-and-shut case.
|
29922283 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this Review, we discuss how IL-17A and IL-17F and their cellular sources might contribute to the immunopathology of SpA.
|
30006601 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA.
|
30038617 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study was undertaken to characterize the presence and composition of ILCs, and investigate whether these cells are an important source of IL-17A, in the synovial tissue (ST) of patients with SpA.
|
30260078 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.
|
30266977 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17A blockade was performed in HLA-B27/human β<sub>2</sub> -microglobulin (hβ<sub>2</sub> m)-transgenic rats, which served as a model for SpA in both prophylactic and therapeutic settings.
|
30390386 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.
|
30602780 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The recent introduction of antibodies blocking IL-17 has expanded the therapeutic options for SpA, as well as psoriasis and psoriatic arthritis.
|
30941119 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
TNFi and IL-17Ai may be used in axSpA, but physicians have more experience with TNFi.
|
31095430 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Translational data in humans have demonstrated an increase in the number of ILC3s responsive to IL-23 and producing either IL-22 or IL-17 in the gut of SpA patients.
|
31197599 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-7 is a cytokine whose ability to stimulate IL-17 production in both innate and adaptive immunity cells has made it a promising target not only for a better understanding of the disease as well as an important potential therapeutic target in patients with SpA.
|
31276000 |
2019 |